![](https://france-biotech.fr/wp-content/uploads/2022/06/Valbiotis.png)
![](https://france-biotech.fr/wp-content/uploads/2022/06/Valbiotis.png)
Valbiotis présente les résultats complémentaires positifs
![](https://france-biotech.fr/wp-content/uploads/2022/06/Valbiotis.png)
Valbiotis accélère sa stratégie de commercialisation
![](https://france-biotech.fr/wp-content/uploads/2022/09/Sans-titre-14-1024x1024.png)
The European Commission designates OptPA, the W253R/R275S tissue
plasminogen activator developed by Op2Lysis, as an orphan drug for the
treatment of non-traumatic spontaneous intracerebral hemorrhage.
![](https://france-biotech.fr/wp-content/uploads/2022/03/IMMUTEP-BLANC.jpg)
Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha
![](https://france-biotech.fr/wp-content/uploads/2022/05/COAVEE-e1651648788950.jpg)
Coave Therapeutics to Collaborate with World-Renowned Institute of Neurodegenerative Diseases of Bordeaux to Develop Gene Therapy Programs Targeting Protein Degradation in Neurodegenerative Disorders
![](https://france-biotech.fr/wp-content/uploads/2022/03/sensorion.jpg)